Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $169.06 million versus the consensus estimate of $165.44 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.